Moneta Group Boosts Eli Lilly Stake by 16%

Investment firm increases holdings in pharmaceutical giant during Q3 2026

Mar. 17, 2026 at 10:53am

Got story updates? Submit your updates here. ›

Moneta Group Investment Advisors LLC raised its position in Eli Lilly and Company (NYSE:LLY) by 16.3% during the third quarter of 2026, according to the company's recent 13F filing with the Securities and Exchange Commission (SEC). The firm now owns 14,493 shares of the pharmaceutical company's stock, valued at $11,058,000.

Why it matters

Eli Lilly is one of the world's largest pharmaceutical companies, with a diverse portfolio of medications and a strong research and development pipeline. Institutional investors closely monitor changes in ownership stakes, as they can signal broader market sentiment and future growth potential for the company.

The details

Moneta Group Investment Advisors LLC purchased an additional 2,033 shares of Eli Lilly during the third quarter, bringing its total holdings to 14,493 shares. The firm's increased stake in Eli Lilly reflects the company's strong financial performance and promising outlook, as the pharmaceutical giant continues to develop new treatments and expand its global reach.

  • Moneta Group Investment Advisors LLC raised its position in Eli Lilly and Company during the third quarter of 2026.

The players

Moneta Group Investment Advisors LLC

An investment management firm that oversees a diversified portfolio of assets, including a significant stake in pharmaceutical giant Eli Lilly and Company.

Eli Lilly and Company

A global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana, that researches, develops, manufactures, and commercializes a broad range of medicines and therapies for patients worldwide.

Got photos? Submit your photos here. ›

The takeaway

Moneta Group's increased investment in Eli Lilly reflects the pharmaceutical company's strong financial performance and promising outlook, as it continues to develop new treatments and expand its global reach. This move by a major institutional investor signals growing confidence in Eli Lilly's long-term growth potential.